Novel Strategy to Improve Immunotherapy & Radiotherapy Response in Gastroesophageal Cancers Utilizing Telomerase-based Oncolytic Virus
Time: 5:00 pm
day: Day One
Details:
- Oncolys has developed a telomerase-based adenovirus OBP-301 (Suratadenoturev) that is conditionally replicating in cancer cells by introducing the human telomerase reverse transcriptase (hTERT)
- OBP-301 (Suratadenoturev) is currently being studied in registrational trials in Esophageal cancer in Japan with a target NDA submission by Q4 2024. It is also being studied in the United States in phase 2 studies in gastric and esophageal cancers
- Encouraging phase 1 and 2 study data using OBP-301 in solid tumors have been published when used as a single agent, as well as in combination with radiation and immunotherapy
